- Home
- SGML vs NUVB Comparison
SGML vs NUVB Comparison
Compare SGML & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- NUVB
- Stock Information
- Founded
- SGML 2011
- NUVB 2018
- Country
- SGML Brazil
- NUVB United States
- Employees
- SGML N/A
- NUVB N/A
- Industry
- SGML Industrial Machinery/Components
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- SGML Industrials
- NUVB Health Care
- Exchange
- SGML Nasdaq
- NUVB Nasdaq
- Market Cap
- SGML 743.4M
- NUVB 837.0M
- IPO Year
- SGML N/A
- NUVB N/A
- Fundamental
- Price
- SGML $5.48
- NUVB $3.17
- Analyst Decision
- SGML Strong Buy
- NUVB Strong Buy
- Analyst Count
- SGML 1
- NUVB 6
- Target Price
- SGML $16.00
- NUVB $8.17
- AVG Volume (30 Days)
- SGML 2.9M
- NUVB 6.5M
- Earning Date
- SGML 08-15-2025
- NUVB 11-05-2025
- Dividend Yield
- SGML N/A
- NUVB N/A
- EPS Growth
- SGML N/A
- NUVB N/A
- EPS
- SGML N/A
- NUVB N/A
- Revenue
- SGML $134,494,014.00
- NUVB $14,355,000.00
- Revenue This Year
- SGML $26.70
- NUVB $332.80
- Revenue Next Year
- SGML $42.31
- NUVB $360.12
- P/E Ratio
- SGML N/A
- NUVB N/A
- Revenue Growth
- SGML N/A
- NUVB 900.35
- 52 Week Low
- SGML $4.25
- NUVB $1.54
- 52 Week High
- SGML $15.56
- NUVB $4.09
- Technical
- Relative Strength Index (RSI)
- SGML 42.14
- NUVB 54.68
- Support Level
- SGML $5.35
- NUVB $3.20
- Resistance Level
- SGML $6.63
- NUVB $3.44
- Average True Range (ATR)
- SGML 0.38
- NUVB 0.26
- MACD
- SGML -0.11
- NUVB -0.00
- Stochastic Oscillator
- SGML 6.62
- NUVB 24.70
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.